@YeshuasKat@EndWokeness@AOC Cortez?..... As In Hernán Cortés, the conqistador who is connected to the fall of the Aztec empire? That's interesting. Makes me wonder about this reparations idea. 🤔
#geni $GENI @GenIncode (AIM: GENI) has experienced a volatile trading period in recent months, with the share price moving from 1.55 pence in mid-September to a peak of 4.45 pence in late October before retracing to 2.60 pence and stabilising near 1.15 pence at the time of writing. The rise was driven primarily by renewed market confidence following an update confirming progress in the FDA Supervisory Review of CARDIO inCode-Score, where the company clarified that outstanding issues had been reduced and a clear path forward had been agreed for additional submissions. Investor optimism was further supported by a statement addressing the share price movement, which highlighted continued commercial momentum in core markets, although it also made the market clear that the company was unaware of any specific recent for the recent share price rise. The subsequent decline reflected profit taking and conservative sentiment ahead of year end, particularly given delays in FDA approval and slower revenue recognition in the NHS. Despite this volatility, GENinCode remains positioned at the intersection of preventive cardiovascular genetics and expanding clinical demand.
The company has reported meaningful operational progress across the first half of 2025, supported by strengthening revenues and expanding international adoption. According to its half year results, income rose 15 percent year on year to £1.6 million, driven by the growth of LIPID inCode and CARDIO inCode-Score in the United States, United Kingdom and Europe. More than forty US clinics now use the platform for coronary heart disease risk assessment, reflecting rising clinical interest in polygenic testing. Ongoing discussions with commercial partners aim to widen distribution once regulatory clearance for CARDIO inCode-Score is achieved. These developments indicate that revenue diversification is beginning to take shape across several major healthcare systems.
Clinical and regulatory progress has remained central to the company’s strategy, particularly in advancing its polygenic risk technologies. The FDA process surrounding CARDIO inCode-Score continues to evolve after the earlier assessment, with GENinCode reporting that remaining data requirements are well defined and expected to be addressed through a new submission in early 2026. Commercial and academic validation is also increasing, supported by a landmark study published in JACC Advances showing improved risk stratification through genetic scoring. Meanwhile, the ROCA ovarian cancer surveillance test has begun NHS deployment under a partnership with UCLH and the North Central London Cancer Alliance, creating a new clinical avenue for the company. Across Europe, sales of LIPID inCode and THROMBO inCode continue to expand in Spain, Italy and Germany.
The commercial outlook has strengthened further with new state approvals in the United States, including authorisation for CARDIO inCode-Score in New York State, one of the country’s most stringent regulatory environments. GENinCode has also entered a collaboration with Thermo Fisher to support broader adoption of its test portfolio, a development that could materially accelerate US growth. While NHS restructuring has delayed expansion in certain regions, the company continues to deliver on targets in Spain and Germany and is scaling its pilot programmes across Catalonia and Extremadura. With cardiovascular disease remaining the world’s leading cause of mortality, the demand for predictive genetic tools is expected to rise. GENinCode now enters 2026 with improved scientific validation, expanding international sales channels and a regulatory pathway that, once completed, may unlock the company’s most significant commercial opportunity to date.
#SCGL $SCGL
Ownership: The company has high insider ownership (56%), with Chairman Chung Lam Law holding approximately 46% of outstanding shares.
Sealand Capital Galaxy Limited (LSE: SCGL) is a Cayman Islands-incorporated investment holding company that focuses on digital marketing, IT, and e-commerce across Emerging Asia, specifically Hong Kong, Macau, and Mainland China.
Core Business Operations
The company operates through three primary segments:
Digital Marketing & Payment: Provides services to enlist merchants onto mobile payment gateways (such as WeChat Pay) and offers digital advertising solutions.
e-Commerce: Sells goods online and provides related consultancy services. This is the company's largest revenue generator.
Software Development: Focuses on the distribution of mobile games and other IT-related support services.
Recent Strategic Developments (2025–2026)
AI Pivot: In January 2026, the company announced a strategic shift to refocus its operations on Artificial Intelligence (AI) and transformative technologies.
Investee Success: Its investee company, Evoo AI PLC, recently secured trademark protection for its "Olive" brand, an AI-driven luxury e-commerce platform.
Leadership Changes: Appointed Chong Sun Terng as Independent Non-Executive Director and Peng as CFO in January 2026.
@SealandCapital_
currently has a consensus broker recommendation of "Outperform" or a "Hold" rating from various analysts. over the next year
The most recent analyst price target range is from £1.65 to £1.77.
The Cat-Themed Memecoin Battle is heating up! 🐾⚔️
🤖 Which one gets your vote today?👇
❤️ Like & 🔁 RT to join the debate
Which ecosystem has the strongest community and the most "pawsitive" momentum this February? 🚀📈
✦
@wikicatcoin
- $WKC #WKC
✦ @ocicattoken
- $OCICAT #OCICAT
✦
@catwmask
- $MASK #MASK
✦
@sachi_coin
- $SACHI #SACHI
Who are you raiding with today? 👇 Drop your ticker below and tag your community to show who is BOSS! 🗣🔊
#BNBChain #Solana #Memecoins #WKC #OCICAT #MASK #SACHI #CatCoins
Most Profitable KOL Trades from Stalkchain Top KOL Tokens (Last 24h)
@tilcrypto made a profit of $17k in $elephant
@risk100x made $3.12k in $agency
@Kevsznx made $370 in $serious
@jijo_exe made $1.04k in $fud and $1.7k in $armpitcoin
@Cupseyy made $1.1k in $entire
@SolanaDali made $1.1k in $soluna
🚨 BREAKING: Stalkchain is now free.
No paywall, no gated data and no premium bait.
If on-chain data is the edge, it shouldn’t be locked behind subscriptions.
Stalkchain is now free for anyone who wants to track wallets, follow flows and make their own trading decisions.
Free tools create stronger traders.